Mizuchi A, Miyachi Y, Tamaki K, Kukita A
J Invest Dermatol. 1976 Aug;67(2):279-82. doi: 10.1111/1523-1747.ep12514266.
Percutaneous absorption was studied in patients following topical application of betametahsone 17-benzoate cream and gel with occlusion by means of a sensitive and specific radioimmunoassay method. Concentrations of betamethasone 17-benzoate in plasma were between 0.3 and 5 ng/ml, indicating approximately 0.05 to 0.3% of the steroid applied to the skin was detected in plasma. Plasma betamethasone 17-benzoate levels increased in proportion to the amount of the steroid applied to the skin. High correlation between plasma betamethasone 17-benzoate levels and percent inhibition of plasma cortisol was also observed. Approximately 3 ng/ml levels of betamethasone 17-benzoate in plasma induced 90% inhibition of plasma cortisol. The data suggest that betamethasone 17-benzoate in gel base was more readily absorbed than in cream base.
采用灵敏且特异的放射免疫分析法，对局部应用倍他米松17 - 苯甲酸酯乳膏和凝胶并封闭的患者进行经皮吸收研究。血浆中倍他米松17 - 苯甲酸酯的浓度在0.3至5纳克/毫升之间，表明涂于皮肤上的类固醇约有0.05%至0.3%在血浆中被检测到。血浆中倍他米松17 - 苯甲酸酯水平与涂于皮肤上的类固醇量成比例增加。还观察到血浆中倍他米松17 - 苯甲酸酯水平与血浆皮质醇抑制百分比之间存在高度相关性。血浆中约3纳克/毫升的倍他米松17 - 苯甲酸酯水平可导致血浆皮质醇90%的抑制。数据表明，凝胶基质中的倍他米松17 - 苯甲酸酯比乳膏基质中的更易被吸收。
